Tagworks Pharmaceuticals
@Tagworkspharma
Followers
234
Following
139
Media
13
Statuses
49
Delivering a new class of ADCs and targeted radionuclide therapies for solid tumors with our proprietary Click-to-Release treatment platform
Nijmegen, The Netherlands
Joined February 2013
We are excited to announce the initiation of our Phase 0/1 clinical trial, sponsored by @radboudumc , evaluating TGW211 in patients with #HER2positive #tumors. Learn more: https://t.co/5oVSE4UBzz
0
1
2
On #WorldCancerResearchDay, we’re reminded that bold scientific innovation is essential. Hear from Marc Robillard, PhD, Tagworks’ co-founder and CSO, about how we’re advancing pioneering in vivo click chemistry into a new standard of care for patients with #solidtumors.
0
0
2
We’re excited to announce that the third dose level has been initiated in our ongoing Phase 1 clinical trial evaluating our lead #ADC program TGW101 in patients with advanced #solidtumors. Learn more: https://t.co/HnbQmzH5uE
0
0
0
We’re innovating for patients with #solidtumors so they can have safer, more effective therapies. Developed with our pioneering Click-to-Release approach, our lead #oncology #ADC program called TGW101 is now recruiting for a #clinicaltrial. Learn more: https://t.co/KsLxQ6AIO9
0
0
5
We’re proud to be featured in a #NatureBiotechnology profile on #radiopharmaceuticals! Our Click-to-Release treatment platform shows potential to remove dose-limiting toxicities to more safely and effectively treat #solidtumors. Read here: https://t.co/G7jKgaSsmY
0
2
12
At #AACR2025, we presented preclinical data on the potential of our Click-to-Release treatment platform to enable safe, tolerable, and potent delivery of therapeutic candidates for #solidtumors. View the posters: https://t.co/Oz7IOuAiNe
#ADCs #oncology
0
1
3
We’re excited to welcome Keith Orford, MD, PhD, as our new CMO! His leadership in #oncology research and clinical drug development will be invaluable as we transition to the clinic. Learn more: https://t.co/oqUs33OsVm
0
0
2
We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: https://t.co/EKirGtjYvH
0
0
12
We look forward to attending #AACR2025! We will share preclinical data that demonstrate the potential of our pioneering Click-to-Release platform to improve the standard of care for patients with #solidtumor #cancers. Learn more: https://t.co/ImKcu4xv12
#ADCs #oncology
0
0
1
We're excited to announce Ken Mills has been appointed our new CEO and that Marc Robillard will continue as CSO & Board member. We look forward to working to bring our Click-to-Release platform and lead ADC program for solid tumors into the clinic in 2025. https://t.co/RFcVYuXonc
0
1
6
Proud to have won the second place for this years LSX Lifestars Awards - Series A of the Year. Great recognition for @Tagworkspharma and our fantastic group of investors ! Congrats to Complement Tx and Adcendo and thanks to @lifestarsawards for this great night out !
0
0
8
A concise synthetic approach to highly reactive click-to-release trans-cyclooctene linkers (Robillard et al. @Tagworkspharma)
chemistry-europe.onlinelibrary.wiley.com
Intramolecular iodolactonization was employed for the efficient and stereoselective conversion of an sTCO click-conjugation precursor to a highly reactive and stable click-cleavable sTCO antibody...
0
5
30
‘Clicked’ drugs: researchers prove the remarkable chemistry in humans Featuring @Tagworkspharma
#portfolio
https://t.co/ckDX4c2ZXl
nature.com
Nature Biotechnology - Bioorthogonal click chemistry is being used in patients to help target cancer medicines and diagnostic imaging agents
0
5
13
Het Nederlandse @Tagworkspharma heeft een grote investeringsronde met succes afgesloten. De financiële impuls biedt het bedrijf de middelen om klinische studies met de belangrijkste kandidaat-ADC in gang te zetten:
sciencelink.net
Click-to-Release technologie kan de klinische inzetbaarheid van antibody drug conjugates (ADC's) vergroten.
1
2
7
We’re excited to announce that we’ve raised $65 Million in Series A financing to advance a pipeline of Click-to-Release Therapeutics ! https://t.co/TKTHHZVGLy
6
3
50
Meet our speakers: Marc Robillard. Cleavable Radioimmunoimaging to increase tumour-to-blood ratio. https://t.co/hPte9yLIif
@dynafluors
@boomchemistry
@Tagworkspharma
@RSC_CBBG
biorxiv.org
One of the main challenges of PET imaging with 89Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing...
0
3
6
We have an exciting opportunity for a synthetic chemist to contribute to the development of new cancer therapies based on Tagworks’ Click-to-Release platform https://t.co/r3cVpoWBVm
0
6
7
Check out this overview of bioorthogonal chemistry. Thanks to Joe Fox and Sam Scinto @FoxGroupUD for leading the charge !
Looking for ways to conduct bioorthogonal chemistry? Have a look at our in-depth overview of this useful toolbox in this week's Primer @FoxGroupUD @WankyuL @klanglab @jenn_prescher @seansn2015 @UCIChemistry @UCIrvine @Tagworkspharma
https://t.co/d7S89NViGb
0
0
8
We have an exciting opportunity for a synthetic chemist to contribute to development of new cancer therapies based on Tagworks’ Click-to-Release platform https://t.co/pJj4nN3HDP
0
23
36
Happy to report that our paper on a new and highly reactive Click-to-Release reaction is now out in @J_A_C_S. Great collaboration between @Tagworkspharma and SyMO-Chem, Syncom, @TUeindhoven, Avipep and Levena. https://t.co/pARkz70aSz
1
17
78